Artiklar och studier

Primära resultat från de pivotala studierna (FUTURE 1 och 2) med sekukinumab inom PsA:

• Mease, Philip J. et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015; 373:1329-1339. →
• McInnes, Iain B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, Volume 386, Issue 9999, 1137-1146 →
• Stand, Vibeke et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017 Jan;76(1):203-207 →

Resultat från studier längre än 1 år:

• Kavanaugh, A et al. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355 →

Sekukinumab som behandling efter TNF-hämmare vid PsA:

• Kavanaugh A., Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. J Rheumatol. 2016 Sep;43(9):1713-7  →

Resultat om effekt med sekukinumab på utveckling av strukturella skador vid PsA:

• van der Heijde, Desirée et al. Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Aug;68(8):1914-21  →

Effekt på PsA med sekukinumab i studier inom måttlig till svår plackpsoriasis:

• Gottlieb Alice B., et al Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. J Drugs Dermatol. 2015 Aug;14(8):821-33  →

Sammanfattande artikel om IL-17A vid patogenesen vid PsA och resultat från kliniska studier med sekukinumab:

• Mease, Philip &.McInnes, Iain B. Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatology and Therapy April 2016, pp 1-25  →

Primära resultat från de pivotala studierna (ERASURE och FIXTURE) med sekukinumab vid måttlig till svår plackpsoriasis:

• Langley Richard G., et al Secukinumab in plaque psoriasis--results of two phase 3 trials [ERASURE and FIXTURE]. N Engl J Med. 2014 Jul 24;371(4):326-38  →
• Strober Bruce, et al, Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7  →

Sammanfattande artikel om IL-17A vid patogenesen vid psoriasis:

• Lowes Michelle, A., et al Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55

Resultat från direkt jämförande studier (FIXTURE och CLAR) med sekukinumab vid måttlig till svår plackpsoriasis:

• Langley RG., et al Secukinumab in plaque psoriasis--results of two phase 3 trials [ERASURE and FIXTURE]. N Engl J Med. 2014 Jul 24;371(4):326-38  →
• Thaçi D., et al, Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400-9  →
• Blauvelt A et al., Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9  →

Sammanställda säkerhetsanalyser:

• van de Kerkhof PC et al, Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Jul;75(1):83-98.e4  →

Utveckling av läkemedelsantikroppar (immunogenicitet):

• Karle, A. et al., Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016 Apr;8(3):536-50  →

Översiktsartiklar om IL-17:

• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007 Feb;13(2):139-45  →